TABLE 1.

Anti‐Fibrotic (nintedanib and pirfenidone) Subsidized Prescribing Conditions for Idiopathic Pulmonary Fibrosis in Australia and New Zealand as of May 2023.

	Australia	New Zealand
Diagnosis	Confirmed by a multidisciplinary meeting	Confirmed by a multidisciplinary meeting
Physiology	FVC ≥50% predicted	FVC between 50% and 90% predicted
	DLCO ≥30% predicted
	FEV1/FVC >0.7
HRCT	Consistent with IPF within previous 12 months
Stopping rule	Nil	≥10% decline in FVC% predicted within a 12 month period

Abbreviations: DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HRCT, high‐resolution computed tomography; IPF, idiopathic pulmonary fibrosis.